Heparin Market Size, Share, Growth, and Industry Analysis, By Type (Heparin Sodium Raw Material Drug, Heparin Calcium Raw Material Drug), By Application (Low Molecular Weight Heparin Preparation, Standard Heparin Preparation) and Regional Forecast to 2035

HEPARIN MARKET OVERVIEW

The global Heparin Market size estimated at USD 3852.52 million in 2026 and is projected to reach USD 6201.94 million by 2035, growing at a CAGR of 17.2% from 2026 to 2035.

The heparin market is growing constantly from year to year, because each year the number of patients with cardiovascular diseases, thromboembolic disorders, and other chronic diseases requiring anticoagulation therapy increases. The global heparin market was estimated to be around USD 9 billion in the year 2023 and segregates by types like unfractionated heparin (UFH), low molecular weight heparin (LMWH) and ultra-low molecular weight heparin (ULMWH). LMWH currently controls a vast market share with predictable response and absence of HIT makes it preferred for use in hospital and home health care facilities. Heparin is predominantly extracted from pigs – China supplies about 90% of the global heparin needs – but synthesized heparin as well as heparin obtained from cows is being developed. Some of the key segments worth mentioning are North America, Europe, and Asia Pacific, because of global issues such as population ageing and rise in healthcare costs driving product demand. The market is further supported by constant research and development, approvals from regulatory bodies and expansion of various product portfolios of the key players such as Pfizer, Baxter International, and Sanofi.

The United States is a leading market for heparin, driven by the high incidence of cardiovascular diseases, surgical procedures, and chronic kidney disease requiring anticoagulant therapy. More than 18.2 million adults in the U.S. have coronary artery disease, while over 500,000 patients receive dialysis annually, creating consistent demand for unfractionated and low-molecular-weight heparin. The country performs approximately 40 million inpatient surgeries each year, where anticoagulants are routinely administered to prevent thromboembolic complications. Strong hospital infrastructure, widespread clinical guidelines, and established pharmaceutical supply chains continue to support heparin utilization across acute and long-term care settings.

• • 

    Download Free sample to learn more about this report.

KEY FINDINGS

• Market Size and Growth: The Heparin Market size was USD 2804.72 Million in 2024, is projected to grow to USD 3120.55 Million by 2025 and exceed USD 4515.15 Million by 2033, with a CAGR of 17.2%

• Key Market Driver: The global rise in cardiovascular surgeries is fueling demand—over 18 million heart-related surgeries are performed annually, with heparin used in nearly 85% of them as a key anticoagulant.

• Major Market Restraint: Supply risks persist due to raw material dependency—around 80% of the world's heparin supply is derived from pig intestines sourced primarily from China, posing risks during epidemics like ASF (African Swine Fever).

• Emerging Trends: Synthetic alternatives are gaining traction—recent clinical trials involving synthetic heparin mimetics have shown 90% comparable efficacy, potentially offering a more stable supply chain.

• Regional Leadership: Europe leads in usage and regulatory oversight, with Germany accounting for over 20% of the region's total hospital-based anticoagulant consumption in 2023 alone.

• Competitive Landscape: The top five companies—Pfizer, Sanofi, Leo Pharma, Baxter, and Fresenius Kabi—collectively control over 60% of global supply, creating a highly consolidated competitive environment.

• Market Segmentation: Low Molecular Weight Heparin (LMWH) makes up nearly 70% of usage due to its ease of administration and fewer side effects compared to unfractionated heparin.

• Recent Development: In early 2024, Leo Pharma received extended FDA approval for its LMWH product for use in pediatric thrombosis—making it the first in the category with such clearance in the U.S.

COVID-19 IMPACT

"Heparin Market""Had a Negative Effect Due to Supply Chain Disruption During COVID-19 Pandemic"

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The COVID-19 had a varied and in most cases, detrimental effects on the heparin market share. First, there was a demand for growth due to the use of heparin for COVID-19 patient with coagulation disorders which amplified heparin production worldwide. However, this surge also led to many problems for the supply chain in the production of raw materials that are derived from animal mucosa in particular as all these led to much confusion on production and shortages. Pandemics and restrictions on movement negatively affected the manufacturing processes, delivery of products and cross border shipments thereby affecting the availability of heparin medical product in a number of countries. Furthermore, the shift of economic burden on the working healthcare facilities and use of resources towards handling COVID-19 minimization impacted the funding as well as the focus on other medical products such as heparin. Secondly, although there was an increased demand for these products temporarily, there was a shift in demand-sensitivity of material supply and thus stability was disrupted. In the long term, these disruptions pointed out the reasons why there was a need to diversify the supply chain to protect markets of specific drugs such as heparin from the effects of world calamities.

LATEST TREND

"Rise of Sustainable and Eco-Friendly Materials Drives Market Growth"

There is a new and the latest trend in the heparin market, known as synthetic heparin, which is caused by a desire to stabilize the supply chain and reduce reliance on animal-based inputs. Heparin is typically derived from the hog intestines; China remains accountable for about 80 percent of the global heparin production. But this dependency has its drawbacks: for example, during the COVID-19 pandemic and other similar outbreaks, such as African swine fever, shortages and high price variation began. As a result; researchers and firms are venturing into synthetic heparin production as this option can offer sustainable and moral best solution. Synthetic heparin operatively seeks to produce the anticoagulant property of natural heparin and at the same time eliminate the ethical issues and or risks associated with zoonotic diseases from animal sourcing or used in heparin production. Consequently, synthetic heparin, if developed, might lower the market risk from supply fluctuations by providing constant supply for important medical processes. Such a change is expected to revolutionize the market and provide a stable, scalable and safe substitute to heparin.

• • 

    Download Free sample to learn more about this report.

HEPARIN MARKET SEGMENTATION

By Type

Based on type, the global market can be categorized into Heparin Sodium Raw Material Drug, Heparin Calcium Raw Material Drug

• hseparin sodium raw material drug: This is an animal derived, a high purity anticoagulant which in its use is mostly in parenteral preparations to avoid forming clots in the blood during operations and in cases of thromboembolic incidents.

• Heparin calcium raw material drug: This preparation is also an anticoagulant similar to heparin sodium and is particularly useful for long-term sought after anticoagulation effects and may be formulated for subcutaneous administration.

By Application

Based on application, the global market can be categorized into Low Molecular Weight Heparin Preparation, Standard Heparin Preparation

• low molecular weight heparin preparation: This form of heparin is smaller in molecular size – thus has more predictable anticoagulant activity and fewer side effects of heparin therapy than heparin, suitable for outpatient and in-hospital administration.

• standard heparin preparation: This is the conventional product of heparin which is used in various medical facilities to provide fast anticoagulation agent for various illnesses and in hospitalism’s.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions. 

Driving Factors

"Increasing Prevalence of Cardiovascular Diseases and Thromboembolic Disorders Boost the Market"

Cardiovascular diseases and thromboembolic disorders such as deep vein thrombosis and pulmonary embolism are growing throughout the world mostly because of an aging population and sedentary lifestyles that include obesity. CVDs still rank high among diseases caused by HHEs, and diseases like DVT as well as PE need proper anticoagulation therapy, thus making heparin necessary. Given heparin acts in preventing formation of blood clots, it is essential in treating the abovementioned life threatening diseases; the rise in the occurrence of these diseases enhances the market automatically. Of these, LMWH is especially used due to constant results and fewer side effects, thereby establishing heparin as an essential factor in handling cardiovascular dysfunction.

"Growing Demand for Anticoagulants in Surgical and Dialysis Procedures Expand the Market"

The growing pool of surgical and dialysis patients across the globe, is a main factor for the heparin market growth. Cardiovascular and orthopedic surgeries are the most common surgeries needing anticoagulation to minimize the occurrence of postoperative thromboembolic complications. For example, dialysis patients who are also at a high risk of clot formation can only receive a safer treatment through use of anticoagulants. The more the population of the world gains easy access to health facilities, the more the population undergo these procedures hence creating the market for heparin. Furthermore, due to outpatient therapy and administration of LMWH, it has attracted much attention in different treatment environments in hospital.

Restraining Factor

"Dependency on Animal-Derived Sources Potentially Impede Market Growth"

The heparin market is under enormous pressure owing its raw material source to animal derived raw material which is mostly derived from the porcine intestine. Shortage of resources for African swine fever, production breakdowns in the market due to diseases as well as stoppage of its production during COVID-19 similarly pose risks on the market. This dependency also bring about several ethical issues concerning animal use in various products hence reduces on the acceptable uptake of heparin especially in markets and to religious groups.

Opportunity

"Synthetic Heparin to Stabilize Supply Chains Create Opportunity for The Product in The Market"

The presence of heparin derived from animal tissues and synthetic heparin offer one of the great chances in the market. This would mean that new synthetic alternatives for such materials would help cut the reliance on animal products thus solving the ethics and supply chain problems. Furthermore, the synthetic heparin production could overcome the problems related to animal sourcing, zoonoses, and variability of product prices while addressing the growth of demand, on the one hand, and provide a definite benefit in terms of a consistent product supply.

Challenge

"Regulatory and Manufacturing Hurdles in Synthetic Heparin Production Could Be a Potential Challenge for Consumers"

This brings the following challenges to the development of synthetic heparin; mainly regulatory and technical in nature. Cosmetic heparin is expected to have the similar therapeutic value as natural heparin, thus, acceptable synthetic heparin undergoes testing that is exhaustive and expensive. Another factor, however, that complicate synthetic heparin availability in the near future is that increasing production to address global demand while controlling expenses remains difficult.

• • 

    Download Free sampleto learn more about this report.

•  

HEPARIN MARKET REGIONAL INSIGHTS

North America

North America especially United States heparin market commands the largest share because of well-developed healthcare infrastructure and high incidence of cardiovascular diseases in the region. Both the United States and Canada are expected to experience steady growth with significant amounts of investment in healthcare, coupled with a growing need for anticoagulant products. Another positive aspect of the US FDA heparin matter is that the agency’s encouragement to research bovine-sourced heparin also expands a regional market.

Europe

Europe is a large consumer of heparin as population ages and number of surgeries rise. Legal requirements and cutting-edge health care industries especially in Germany and UK back the use of heparin. European countries are also involved in R&D in search of heparin sources to make supply chains more secure.

Asia

The Asia-Pacific is experiencing significant growth in heparin market owing to increasing healthcare spending, rising prevalence of cardiovascular diseases, an ageing population. This makes China as the global producer of porcine-derived heparin strengthen regional hegemony while India their counterparts as consumers resulting from high rates of CVD and related surgeries.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market Through Innovation and Market Expansion"

Prominent industry players involved in the heparin market include Pfizer Inc., Baxter International, Sanofi, Leo Pharma A/S, B. Braun Melungeon AG. These companies always introduce innovations and transform themselves through strategic partnerships. For instance, Baxter has upstream activities directed toward refining production capacity, while Sanofi and Pfizer have increasing emphasis on new formulas for increasing needs. Other firms that are from China include Hebei Changshan Biochemical Pharmaceutical Company that also provides raw material. Additional market participants are Dr. Reddy’s Laboratories and Hi k m a Pharmaceuticals, which complement market dynamics with differentiated portfolios and geographic initiatives, which lead to heparin availability worldwide.

List of Market Players Profiled

• Dongcheng Biochemicals (China)
• Jiulong Biochemicals (China)
• Opocrin (Italy)
• Hepalink (China)

KEY INDUSTRY DEVELOPMENT

November 2023: The company certainly made a breakthrough with DefenCath which gained FDA approval a taurolidine and heparin formulation which is intended to prevent bloodstream infections in dialysis patients.

Five Recent Developments (2023-2025)

• 2025: Fresenius Kabi expanded the availability of injectable heparin sodium products in the U.S., strengthening hospital supply and improving access to critical anticoagulant therapies.
• 2025: Pfizer enhanced manufacturing and supply chain resilience for sterile injectable anticoagulants, including heparin products, to support growing demand from healthcare providers.
• 2024: Hikma Pharmaceuticals broadened its portfolio of generic injectable heparin formulations, increasing production capacity to support hospitals and emergency care facilities.
• 2024: B. Braun expanded its prefilled heparin flush syringe offerings with improved packaging and safety features to reduce medication errors in clinical settings.
• 2023: Amphastar Pharmaceuticals increased manufacturing capacity for heparin sodium injection to improve supply continuity and meet rising demand from hospitals, dialysis centers, and surgical facilities.

REPORT COVERAGE

Heparin is in the right market for steady growth based on constantly rising instances of cardiovascular diseases and medical operations that require the use of anticoagulants. There is still activity and improvements such as synthetic heparin which has the potential to meet the supply chain issues. Possible threats such as relying on animal derived sources, and inconsistent raw material supply, probable threats such as limitation through synthetic substitutes, and FDA support for such sources may guarantee buoyancy. According to estimations, North America, Europe, and Asia-Pacific are to become significant for the development of demand. In summary, it will be possible to see that the market has a positive trend in the development, whereas further attention to the occurrence of new needs in the healthcare market can be expected.